logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Julian Stanley Kroin

This inventor holds 14 USPTO granted patents. Top assignee: Eli Lilly and Company. Active years: 1990-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julian Stanley Kroin. Retrieved from https://idiyas.com/inventor/julian-stanley-kroin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14

% Patents Active = 85.7

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 32(Granted Patents)


Company Filing History:

goldMedal14 out of 4,514 
 
Eli Lilly and Company
 patents

Years Active: 1990-2012

Loading Chart...
14 patents (USPTO):Explore Patents
1. 8093302 - Substituted tetralins as selective estrogen receptor-β agonists (2012-01-10),
2. 6743794 - Methods and compounds for inhibiting MRP1 (2004-06-01),
3. 6369070 - Methods for inhibiting mrp1 (2002-04-09),
4. 6180633 - Drug resistance and multidrug resistance modulators (2001-01-30),
5. 6130219 - Drug resistance and multidrug resistance modulators (2000-10-10),
6. 6025359 - Drug resistance and multidrug resistance modulators (2000-02-15),
7. 5776939 - Drug resistance and multidrug resistance modulators (1998-07-07),
8. 5644043 - 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates (1997-07-01),
9. 5594155 - Anomeric fluororibosyl amines (1997-01-14),
10. 5574021 - Methods of treatment using 2',3'-dideoxy-2',2'-difluoronucleosides (1996-11-12),
11. 5541345 - Anomeric fluororibosyl amines (1996-07-30),
12. 5480992 - Anomeric fluororibosyl amines (1996-01-02),
13. 5430026 - 2'-deoxy-2',2'-difluoro (4-substituted pyrimidine) nucleosides, bicyclic (1995-07-04),
14. 4914028 - Method of preparing beta-2',2'-difluoronucleosides (1990-04-03),

Title: Exploring the Innovations of Julian Stanley Kroin

Introduction

Julian Stanley Kroin is an accomplished inventor based in Indianapolis, IN, who has made significant contributions to the field of pharmaceutical sciences. With a portfolio of 14 patents, Kroin's innovations focus on addressing various health conditions through the development of novel compounds and methodologies.

Latest Patents

Among Kroin's latest patents are significant advancements in medicinal chemistry, including "Substituted tetralins as selective estrogen receptor-β agonists." This invention relates to unique tetralin compounds and their pharmaceutical compositions that hold promise for treating diseases mediated by the ER-β receptor. Conditions targeted by his inventions include nocturia, benign prostatic hypertrophy, obesity, cancer, and depression, among others.

Another notable patent is "Methods and compounds for inhibiting MRP1," which presents a method for inhibiting Multidrug Resistance Protein 1 (MRP1) in mammals. This work emphasizes the use of specific compounds to combat health issues related to drug resistance in various diseases.

Career Highlights

Julian Kroin has established a prominent career within Eli Lilly and Company, a leading global pharmaceutical firm known for its innovative approaches to medicine. His role there has allowed him to leverage his expertise in medicinal chemistry and contribute to groundbreaking research that impacts patient care.

Collaborations

Kroin has had the opportunity to collaborate with esteemed colleagues such as Larry W Hertel and Bryan Hurst Norman. These collaborations have likely enriched his work and expanded the possibilities for innovative treatment solutions.

Conclusion

Julian Stanley Kroin's contributions to the field of pharmaceuticals not only underscore his inventiveness but also highlight the potential for improving human health through targeted therapies. His patents and ongoing research with Eli Lilly and Company continue to inspire advancements in treatment for critical medical conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…